J.B. Chemicals & Pharmaceuticals financials

·Pharma & HealthChart ›
Latest results Q4 FY26 · Jan–Mar 2026
Revenue
₹904cr−4.8% on Q4 FY25
Net profit
₹101cr−30.4% on Q4 FY25
EBITDA margin
22.2%−1.6 pts on Q4 FY25
EPS
₹6.35−32.2% on Q4 FY25

Quarterly results

Every quarter ›
₹ croreQ4 FY26Q4 FY25Change
Revenue904949−4.8%
EBITDA201226−11.2%
EBITDA margin22.2%23.9%−1.6 pts
Profit before tax135193−30.2%
Net profit101146−30.4%
EPS₹6.35₹9.36−32.2%

Over time

Q4 FY26 · Jan–Mar 2026latest
Revenue₹904 crNet profit₹101 crNet margin11.2%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
849432453269
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.11.00.00.0
0.013.8357548
4,1483,9183,4843,149
+5.9%+12.5%+10.6%—
1,1071,032897696
26.7%26.3%25.7%22.1%
925861759581
709660553410
17.1%16.8%15.9%13.0%
₹44.18₹41.07₹34.41₹25.52
+7.6%+19.4%+34.8%—
704902801626
0.0−120−261−765
704782539−139
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMIPCALABSAILIFENHNEULANDLABACUTAASNATCOPHARM
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
- Cash, Equiv & ST Investments269.1452.9432.2849.1
+ Minority Interest0.00.01.03.1
+ Total Debt548.2357.113.80.0
Revenue3,149.33,484.23,918.04,147.8
Growth %, YoY—+10.6+12.5+5.9
EBITDA695.8896.91,031.81,107.4
Margin %22.0925.7426.3426.70
EBIT581.3758.6860.8924.9
Net Income410.0552.6659.6709.5
Margin %13.0215.8616.8317.10
EPS, Adj (current shares)25.5234.4141.0744.18
Growth %, YoY—+34.8+19.4+7.6
Cash from Operations625.6800.6902.5703.9
Capital Expenditures-765.0-261.4-120.3-0.0
Free Cash Flow-139.3539.3782.2703.9
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

J.B. Chemicals & Pharmaceuticals financials and key ratios

Figures from the company's filings with NSE

In FY26 its consolidated net profit was ₹709 crore on revenue of ₹4,148 crore. It had no borrowings on 31 March 2026. Promoters held 48.80% of the shares on 31 March 2026.

Latest balance sheet
31 March 2026
Shareholding pattern
31 March 2026

J.B. Chemicals & Pharmaceuticals at a glance · consolidated

ROE (FY26)
18.7%−2.1 pts vs FY25ROCE 23.1%
Debt to equity
0.00net cash ₹885 Cr
Promoter holding
48.80%+1.3 pts vs 31 Dec 202531 March 2026
Net worth
₹4,159 Cr+21.1% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹704 Cr−10.0% vs FY25
EPS (FY26)
₹45.16

Questions

Is J.B. Chemicals & Pharmaceuticals debt free?

Yes. J.B. Chemicals & Pharmaceuticals had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹885 crore of cash, bank balances and current investments.

What is the J.B. Chemicals & Pharmaceuticals debt to equity ratio?

J.B. Chemicals & Pharmaceuticals' debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹4,159 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the J.B. Chemicals & Pharmaceuticals net worth?

J.B. Chemicals & Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹4,159 crore on 31 March 2026, up 21.1% from ₹3,433 crore a year earlier.

What is the J.B. Chemicals & Pharmaceuticals ROE and ROCE?

In FY26, J.B. Chemicals & Pharmaceuticals' return on equity (ROE) was 18.7% and its return on capital employed (ROCE) was 23.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 20.8% and ROCE 25.4%.

What is the J.B. Chemicals & Pharmaceuticals promoter holding?

Promoters held 48.80% of J.B. Chemicals & Pharmaceuticals on 31 March 2026, up 1.25 percentage points from 47.55% the previous quarter and up 0.96 percentage points from 47.84% a year earlier, according to the shareholding pattern filed with NSE.

What is the J.B. Chemicals & Pharmaceuticals shareholding pattern?

On 31 March 2026, J.B. Chemicals & Pharmaceuticals' shares were held by promoters 48.80%, foreign portfolio investors (FII/FPI) 16.33%, domestic institutions (DII) 21.38% (including mutual funds at 19.00%) and retail and other non-institutional investors 13.48%. Over the year, FII holding was down 1.97 percentage points from 18.30% and DII holding was up 2.66 percentage points from 18.72%.

What is the J.B. Chemicals & Pharmaceuticals book value per share?

J.B. Chemicals & Pharmaceuticals' book value per share was ₹258.98 on 31 March 2026: shareholders' equity of ₹4,159 crore divided by the 16.06 crore shares in issue, up 17.4% from ₹220.51 a year earlier.

What is the J.B. Chemicals & Pharmaceuticals EPS?

J.B. Chemicals & Pharmaceuticals' basic earnings per share (EPS) were ₹45.16 in FY26, against ₹42.45 in FY25. Over the last four quarters (Q1 FY26 to Q4 FY26) they add up to ₹45.26.

What is the J.B. Chemicals & Pharmaceuticals dividend in 2026 and its record date?

In 2026, J.B. Chemicals & Pharmaceuticals has declared two dividends totalling ₹22 a share: ₹12.70 (interim) with record date 11 February 2026 and ₹9.30 with record date 29 May 2026.

What is the J.B. Chemicals & Pharmaceuticals free cash flow?

In FY26, J.B. Chemicals & Pharmaceuticals generated ₹704 crore of cash from operations and spent ₹0 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹704 crore. In FY25 it was ₹782 crore.

What are the J.B. Chemicals & Pharmaceuticals latest quarterly results?

J.B. Chemicals & Pharmaceuticals' latest results are for Q4 FY26 (January–March 2026), filed on 11 May 2026: consolidated net profit ₹101 crore, down 30.4% from ₹146 crore in Q4 FY25; revenue from operations ₹904 crore, down 4.8% year on year.

What is the J.B. Chemicals & Pharmaceuticals revenue and profit in FY26?

In FY26 (April 2025–March 2026), J.B. Chemicals & Pharmaceuticals' consolidated net profit was ₹709 crore, up 7.6% from ₹660 crore in FY25, on revenue from operations of ₹4,148 crore (up 5.9%). Over three years, from FY23, net profit was up 73.1%.

How does J.B. Chemicals & Pharmaceuticals compare with its peers?

On FY26 consolidated figures, against Torrent Pharma, Alkem Laboratories and Ipca Laboratories: J.B. Chemicals & Pharmaceuticals' operating margin of 22.3% is the second highest of the four (Torrent Pharma 24.6%, Alkem Laboratories 17.8%, Ipca Laboratories 16.2%; peer average 19.5%); its return on equity of 18.7% is the second highest of the four (Torrent Pharma 27.1%, Alkem Laboratories 17.8%, Ipca Laboratories 15.2%; peer average 20.0%); its revenue growth over three years of 9.6% a year is the third highest of the four (Torrent Pharma 13.3% a year, Alkem Laboratories 8.3% a year, Ipca Laboratories 15.6% a year; peer average 12.4% a year).

J.B. Chemicals & Pharmaceuticals vs Torrent Pharma: how do they compare?

In FY26, J.B. Chemicals & Pharmaceuticals earned net profit of ₹709 crore on revenue of ₹4,148 crore, against ₹2,163 crore on ₹13,980 crore for Torrent Pharma. J.B. Chemicals & Pharmaceuticals' operating margin was 22.3% (Torrent Pharma 24.6%) and its return on equity 18.7% (Torrent Pharma 27.1%).

Where do these J.B. Chemicals & Pharmaceuticals figures come from?

From J.B. Chemicals & Pharmaceuticals' own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.